一、回购股份的基本情况 天臣国际医疗科技股份有限公司（以下简称"公司"）于 2023 年 12 月 27 日召 开第二届董事会第十次会议，审议通过了《关于<公司以集中竞价交易方式回购公 司股份的方案>的议案》，同意公司以集中竞价交易方式回购公司股份，回购资金 总额不低于人民币 1,800 万元（含），不超过人民币 3,600 万元（含），回购价格不 超过人民币 30.00 元/股，回购期限自公司董事会审议通过回购方案之日起 12 个月 内 。 具 体 内 容 详 见 公 司 于 2023 年 12 月 28 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）上披露的《天臣国际医疗科技股份有限公司关于以集中竞价交 易方式回购公司股份的回购报告书》（公告编号：2023-048）。 公司于 2024 年 7 月 9 日召开第二届董事会第十五次会议，审议通过了《关于 证券代码：688013 证券简称：天臣医疗 公告编号：2025-059 天臣国际医疗科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准 ...

Core Viewpoint - Tianchen Medical (688013) announced a cash dividend of 0.5 yuan per share (including tax) for the first half of 2025, with the record date set for October 15, 2025, and the ex-dividend date on October 16, 2025 [1][3] Trading Information Summary - As of September 30, 2025, Tianchen Medical's stock closed at 60.36 yuan, up 1.41%, with a turnover rate of 1.43% and a trading volume of 11,600 shares, resulting in a transaction amount of 69.6488 million yuan [1] - On the same day, the net inflow of main funds was 5.2935 million yuan, accounting for 7.6% of the total transaction amount; the net inflow of speculative funds was 5.936 million yuan, accounting for 8.52%; while retail investors experienced a net outflow of 11.2295 million yuan, accounting for 16.12% [1][3] Company Announcement Summary - Tianchen Medical's cash dividend distribution was approved at the third extraordinary general meeting of shareholders on September 12, 2025, with a total cash dividend amounting to 40.3317695 million yuan (including tax) based on 80,663,539 shares participating in the distribution [1][2] - The company will not conduct capital reserve transfers to increase share capital or issue bonus shares as part of this dividend distribution [2]

!"#$%&'()*+ , - ./!0123456789: ;<=>?)@ A B@C#DEF 上海市山西北路 99 号苏河湾中心 25-28 层 邮编：200085 25-28/F, Suhe Centre, No.99 North Shanxi Road, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 二零二五年九月 国浩律师（上海）事务所 专项法律意见书 国浩律师（上海）事务所 关于天臣国际医疗科技股份有限公司 1. 本所律师已严格履行了法定职责，遵循了勤勉尽责和诚实信用原则，根据 《公司法》《证券法》《回购规则》《回购指引》等相关法律、法规及规范性文件 的规定及本专项法律意见书出具日前已经发生或者存在的事实，对与出具本专项 法律意见书有关的所有文件资料及证言进行了审查判断，对公司本次差异化分红 进行了充分的核查验证，保证本专项法律意见书不存在虚假记载、误导性陈述或 者重大遗漏。 2. 公司及相关方已保证：其已经向本所律师提供 ...

证券代码：688013 证券简称：天臣医疗 公告编号：2025-057 二、分配方案 1. 发放年度：2025年半年度 2. 分派对象： 天臣国际医疗科技股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/10/15 | 2025/10/16 | 2025/10/16 | 一、通过分配方案的股东会届次和日期 本次利润分配方案经天臣国际医疗科技股份有限公司（以下简称"公司）2025 年 9 月 12 日的2025年第三次临时股东会审议通过。 3. 差异化分红送转方案： （1）本次差异化分红方案 根据公司 2025 年第三次临时股东会审议通过的《关于公司<2025 年半年度利 润分配方案>的议案》，公司以实施权益分派股权登记日登记的总股本扣减公司回 购专用证券账户中股份为基数，向股权登记日登记在册的全体股东每 10 股派发现 金红利人民币 5.00 元（含税） ...

Core Insights - The medical device sector experienced a slight increase of 0.39% on September 29, with Tianzhihang leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Medical Device Sector Performance - Tianzhihang (688277) saw a closing price of 18.47, with a rise of 7.70% and a trading volume of 172,400 shares, amounting to a transaction value of 315 million yuan [1] - Jimin Health (603222) closed at 11.30, up 5.51%, with a trading volume of 494,600 shares and a transaction value of 556 million yuan [1] - Dongxing Medical (301290) closed at 29.32, increasing by 4.86%, with a trading volume of 99,500 shares and a transaction value of 29.67 million yuan [1] - Other notable performers included Sainuo Medical (688108) with a 4.82% increase and a closing price of 27.83, and Tianchen Medical (688013) with a 3.89% increase, closing at 59.52 [1] Capital Flow Analysis - The medical device sector saw a net inflow of 85.63 million yuan from institutional investors, while retail investors contributed a net inflow of 46.52 million yuan [2] - However, speculative funds experienced a net outflow of 132 million yuan [2] Individual Stock Capital Flow - Sainuo Medical (688108) had a net inflow of 111 million yuan from institutional investors, but a net outflow of 68.66 million yuan from speculative funds [3] - Mairui Medical (300760) also saw a significant net inflow of 107 million yuan from institutional investors, with a net outflow of 76.49 million yuan from speculative funds [3] - Jimin Health (603222) had a net inflow of 53.49 million yuan from institutional investors, while speculative funds saw a net outflow of 43.40 million yuan [3]

Group 1 - The core viewpoint of the news is that Tianchen Medical has shown significant stock performance, with a year-to-date increase of 251.77%, despite a recent decline of 6.85% over the last five trading days [1] - As of September 29, Tianchen Medical's stock price reached 58.50 CNY per share, with a market capitalization of 4.748 billion CNY [1] - The company specializes in the research, innovation, and production of high-end surgical staplers, with its main business revenue composition being 77.92% from non-powered products and 22.08% from powered products [1] Group 2 - For the first half of 2025, Tianchen Medical reported a revenue of 156 million CNY, representing a year-on-year growth of 17.66%, and a net profit attributable to shareholders of 48.2116 million CNY, which is a 67.10% increase compared to the previous year [2] - The number of shareholders decreased by 6.64% to 4,148, while the average circulating shares per person increased by 7.11% to 19,564 shares [2] - Since its A-share listing, Tianchen Medical has distributed a total of 171 million CNY in dividends, with 139 million CNY distributed over the past three years [2]

Core Viewpoint - Tianchen Medical (688013) has established a dual-engine strategy focusing on minimally invasive capabilities driven by end-execution components and an intelligent surgical robot ecosystem supported by the M platform, with a focus on 5mm ultra-minimally invasive technology and smart electric surgical robots [1][3]. Group 1: Company Performance - As of September 19, 2025, Tianchen Medical's stock closed at 62.16 yuan, down 7.57% from the previous week [1]. - The company's current total market capitalization is 5.045 billion yuan, ranking 71st out of 126 in the medical device sector and 3263rd out of 5153 in the A-share market [1]. Group 2: Research and Development - R&D expenses accounted for 12.10% of revenue, with 53 new authorizations, including 44 core technology invention patents [2][4]. - The M platform and I exploration of the intelligent surgical platform project have entered the design verification stage, focusing on intraoperative image recognition, operational assistance, and data analysis [1][4]. Group 3: International and Domestic Business Development - The company is pursuing a dual-drive strategy for domestic and overseas markets, with overseas revenue of 53.4701 million yuan, accounting for 34.24% of total revenue, and products covering 64 countries and regions [3][4]. - In the domestic market, the company emphasizes "clinical quality first + reasonable pricing" to ensure the supply and quality of centralized procurement products while promoting market access, product iteration, and channel penetration [3].

Core Points - Tianchen Medical (688013) stock price increased by 17.76% to 67.25 CNY as of September 12, 2025, reaching a nearly one-year high of 68.0 CNY during the week [1] - The company's total market capitalization is 5.484 billion CNY, ranking 66th out of 126 in the medical device sector and 3074th out of 5153 in the A-share market [1] Company Announcements - Tianchen Medical will participate in the 2025 semi-annual performance briefing for the medical device industry on September 17, 2025, with key executives present for investor interaction [1][4] - The company approved a proposal to use up to 200 million CNY of temporarily idle raised funds for cash management, with a usage period of 12 months [2][4] - The company and its subsidiaries plan to apply for a total credit limit of up to 300 million CNY from banks within 12 months [2][4] - The company’s shareholders meeting approved the 2025 annual audit firm reappointment and the 2025 semi-annual profit distribution plan, with over 99.98% approval from ordinary shareholders [2][4]

国投证券股份有限公司 关于天臣国际医疗科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 国投证券股份有限公司（以下简称"国投证券"、"保荐机构"）作为天臣国 际医疗科技股份有限公司（以下简称"天臣医疗"或"公司"）首次公开发行股 票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上市 公司募集资金监管规则》《上海证券交易所科创板上市公司自律监管指引第 1 号 —规范运作》等相关规定，对天臣医疗使用暂时闲置募集资金进行现金管理进行 了审慎核查，发表核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2020 年 9 月 1 日出具的《关于同意天臣国 际医疗科技股份有限公司首次公开发行股票注册的批复》（证监许可[2020]2020 号），公司获准向社会公开发行人民币普通股 20,000,000 股，每股发行价格为人 民币 18.62 元，募集资金总额为 37,240.00 万元，扣除承销费等发行费用（不含 本次公开发行股票发行费用可抵扣增值税进项税额）4,860.53 万元后，募集资金 净额为 32,379.47 万元，上述资金已于 2020 年 9 月 23 日全 ...

Group 1 - The core point of the article is that Tianchen Medical (SH 688013) held its 29th meeting of the second board of directors on September 12, 2025, to discuss a proposal for applying for a comprehensive credit line from banks [1] - For the fiscal year 2024, Tianchen Medical's revenue composition is 99.99% from medical devices and 0.01% from other businesses [1] - As of the report, Tianchen Medical has a market capitalization of 5.5 billion yuan [1]